Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus DCF versus DCF alone in resectable esophageal squamous cell carcinoma
ChiCTR2000029419Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab, docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Xijing Hospital. Primary endpoints: R0 resection rate and 3-year overall survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
camrelizumabdocetaxelcisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000029419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029419.